Verastem Oncology Reports Clinically Meaningful Response Rates in Phase 2 Study in Ovarian Cancer
Verastem Oncology (Nasdaq: VSTM) has reported clinically meaningful response rates in a Phase 2 trial evaluating the safety and efficacy of avutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer (LGSOC).
There are currently no FDA or EMA approved treatments for LGSOC, which remains an area of unmet need.
The company’s shares soared more than 200% following the news.
Highlights
The study demonstrated that treatment with the combination of avutometinib and defactinib resulted in an objective response rate (ORR) of 45% and tumor shrinkage in 86% of evaluable patients.Safety and tolerability was favorable.
The drug combination has been granted Breakthrough Therapy Designation granted by theFDA for the treatment of recurrent LGSOC.
The Company is finalizing the design of a randomized confirmatory trial with the FDA, planned for the second half of 2023.
The study’s results will be presented in a poster discussion session at the American Society of Clinical Oncology Annual Meeting.
About Verastem
Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition.
